Author

Jian-Hua Chen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study

Mefatinib, a novel second-generation epidermal growth factor (EGFR) tyrosine kinase inhibitor that has shown promising antitumor activity in targeting non-small cell lung cancer (NSCLC) with common and uncommon EGFR-activating mutations. In this phase III, randomized, double-blind trial in China, 336 eligible patients...

Jia Yu, Anwen Xiong, Qi-Ming Wang et al. · Signal Transduction and Targ... · 0 citations

Review Aug 2026

Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial.

PURPOSE Uncommon epidermal growth factor receptor (EGFR) mutations account for ∼10% of EGFR-altered non-small cell lung cancer (NSCLC) and show heterogeneous sensitivity to EGFR-tyrosine kinase inhibitors (TKIs), with limited prospective evidence to inform first-line therapy. Sutetinib is an irreversible EGFR-TKI. We a...

Feng-Ying Wu, Wei Zhang, Yan-Qiu Zhao et al. · Journal of Thoracic Oncology · 0 citations

Review Open access Aug 2026

Temporal trends in small-cell lung cancer trials registered on ClinicalTrials.gov: a cross-sectional analysis (1996–2025)

Background Small-cell lung cancer (SCLC) has undergone important therapeutic advances in recent years, including the incorporation of programmed death-ligand 1 (PD-L1) inhibitors into first-line treatment for extensive-stage disease and the emergence of novel therapies for relapsed disease. Whether the characteristics...

Jia-Ren Cui, Jian-Hua Chen, Hong-Ming Zhang · Journal of Thoracic Disease · 0 citations